Verus Capital Partners LLC decreased its stake in Genprex, Inc. (NASDAQ:GNPX – Free Report) by 37.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 55,500 shares of the company’s stock after selling 33,000 shares during the quarter. Verus Capital Partners LLC’s holdings in […]
/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.
/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.
/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.
Genprex, Inc. (NASDAQ:GNPX – Get Free Report)’s share price fell 8.9% on Wednesday . The stock traded as low as $0.79 and last traded at $0.79. 427,355 shares traded hands during mid-day trading, a decline of 15% from the average session volume of 501,663 shares. The stock had previously closed at $0.87. Genprex Trading Up […]